Hypothesis

Age‑associated mtDNA mutations deplete ATP in colonic enterocytes, compromising ATP‑dependent chaperones and the VCP/p97 segregase that extracts misfolded tight‑junction proteins for proteasomal degradation. When ATP falls, VCP activity stalls, leading to accumulation of ubiquitinated ZO‑1 and occludin that are shunted to lysosomal autophagy, ultimately degrading junctional complexes despite unchanged gene expression. This energetic proteostasis failure explains the protein‑gene discordance observed in aging gut barriers and provides a direct mechanistic bridge from mtDNA damage to barrier leak and local inflammaging.

Mechanistic Rationale

1. ATP shortage – OXPHOS deficiency from mtDNA lesions reduces cytosolic ATP below the threshold needed for VCP/p97 ATPase cycles (4).
2. VCP/p97 dependence – VCP extracts ubiquitinated junctional proteins from complexes; its inhibition causes ZO‑1/occludin accumulation and subsequent autophagic clearance (5).
3. Proteostasis shift – Low ATP favors autophagy over proteasome, diverting ubiquitinated junctional proteins to lysosomes where they are degraded.
4. Barrier outcome – Loss of ZO‑1/occludin weakens paracellular sealing, increasing permeability and enabling microbial product translocation that fuels IFN‑γ, IL‑6, IL‑1β production (2).

Testable Predictions

• Prediction 1: In aged mice or PolG mutator enterocytes, ATP levels will correlate positively with VCP activity and inversely with ZO‑1/occludin ubiquitination.
• Prediction 2: Pharmacological activation of VCP (e.g., with CB-5083 low‑dose) or ATP restoration (mitochondrial‑targeted NAD+ booster) will reduce junctional protein loss and restore barrier resistance.
• Prediction 3: Blocking autophagy (chloroquine) in ATP‑depleted crypts will cause accumulation of ubiquitinated ZO‑1/occludin and exacerbate leak, whereas proteasome inhibition (MG‑132) will have a lesser effect.

Experimental Approach

• Isolate colonic crypts from young, aged, and mtDNA‑mutator mice; measure Seahorse ATP production, VCP ATPase activity, and ubiquitin‑ZO‑1/occludin levels by immunoblot.
• Treat crypts with oligomycin to acutely drop ATP; assess junctional protein half‑life via cycloheximide chase and lysosomal vs proteasomal inhibitors.
• In vivo, feed aged mice mitochondrially targeted SS‑31 peptide or NR; quantify FITC‑dextran permeability, zonulin, and cytokines.
• Use intestinal epithelial‑specific VCP knockout to test whether phenocopying ATP loss accelerates barrier decline independent of mtDNA status.

Potential Confounds

• Compensatory upregulation of glycolytic ATP may mask effects; monitor ECAR and use 2‑DG to clamp glycolysis.
• Cell‑type heterogeneity: ensure analyses are restricted to enterocytes via EpCAM+ sorting.

Implications

If proven, this hypothesis shifts the focus from nuclear gene expression to mitochondrial energetic control of junctional protein quality control. It suggests that preserving ATP‑dependent segregase activity could be a viable strategy to mitigate age‑related barrier dysfunction and its contribution to inflammaging, independent of nuclear genome interventions.

References

[1] Age-associated mitochondrial DNA mutations cause metabolic remodeling [2] Age-Associated Remodeling of the Intestinal Epithelial Barrier [3] Chronological Ageing on Tight Junction-related Gene Expression [4] Mitochondrial dysfunction occurs before transport or tight junction deficits [5] Apoptosis of enterocytes and nitration of junctional complex proteins [6] Mitochondrial DNA mutations in ageing and cancer